Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid

Petros Takousis; Angélique Sadlon; Jessica Schulz; Inken Wohlers; Valerija Dobricic; Lefkos Middleton; Christina M. Lill; Robert Perneczky; Lars Bertram

doi:10.1016/j.jalz.2019.06.4952

Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid

Petros Takousis, Angélique Sadlon, Jessica Schulz, Inken Wohlers, Valerija Dobricic, Lefkos Middleton, Christina M. Lill, Robert Perneczky, Lars Bertram^*

^*Corresponding author for this work

160 Citations (Scopus)

Abstract

Introduction: Several microRNAs (miRNAs) have been implicated in Alzheimer's disease pathogenesis, but the evidence from individual case-control studies remains inconclusive. Methods: A systematic literature review was performed, followed by standardized multistage data extraction, quality control, and meta-analyses on eligible data for brain, blood, and cerebrospinal fluid specimens. Results were compared with miRNAs reported in the abstracts of eligible studies or recent qualitative reviews to assess novelty. Results: Data from 147 independent data sets across 107 publications were quantitatively assessed in 461 meta-analyses. Twenty-five, five, and 32 miRNAs showed studywide significant differential expression (α < 1·08 × 10⁻⁴) in brain, cerebrospinal fluid, and blood-derived specimens, respectively, with 5 miRNAs showing differential expression in both brain and blood. Of these 57 miRNAs, 13 had not been reported in the abstracts of previous original or review articles. Discussion: Our systematic assessment of differential miRNA expression is the first of its kind in Alzheimer's disease and highlights several miRNAs of potential relevance.

Original language	English
Journal	Alzheimer's and Dementia
Volume	15
Issue number	11
Pages (from-to)	1468-1477
Number of pages	10
ISSN	1552-5260
DOIs	https://doi.org/10.1016/j.jalz.2019.06.4952
Publication status	Published - 11.2019

Funding

This work was supported by the EU (grant number IMI_GA_EMIF-115372 to L.B.), the Deutsche Forschungsgemeinschaft - DFG (grant number BE2287/8-1 to L.B.), a scholarship of the Peter und Traudl Engelhorn Foundation (to I.W.), an “Exzellenzmedizin” thesis research scholarship of the University of Lübeck (to J.S.), Stevenage Bioscience Catalyst/Imperial Innovations (grant number 7164/SBC014RP to R.P.), and an Imperial College President's PhD scholarship (to A.S.). All funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 10 Reduced Inequalities

Research Areas and Centers

Research Area: Medical Genetics

Access to Document

10.1016/j.jalz.2019.06.4952

Cite this

@article{fef82f0edd45466db0d47e93dc8879da,

title = "Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid",

abstract = "Introduction: Several microRNAs (miRNAs) have been implicated in Alzheimer's disease pathogenesis, but the evidence from individual case-control studies remains inconclusive. Methods: A systematic literature review was performed, followed by standardized multistage data extraction, quality control, and meta-analyses on eligible data for brain, blood, and cerebrospinal fluid specimens. Results were compared with miRNAs reported in the abstracts of eligible studies or recent qualitative reviews to assess novelty. Results: Data from 147 independent data sets across 107 publications were quantitatively assessed in 461 meta-analyses. Twenty-five, five, and 32 miRNAs showed studywide significant differential expression (α < 1·08 × 10−4) in brain, cerebrospinal fluid, and blood-derived specimens, respectively, with 5 miRNAs showing differential expression in both brain and blood. Of these 57 miRNAs, 13 had not been reported in the abstracts of previous original or review articles. Discussion: Our systematic assessment of differential miRNA expression is the first of its kind in Alzheimer's disease and highlights several miRNAs of potential relevance.",

author = "Petros Takousis and Ang{\'e}lique Sadlon and Jessica Schulz and Inken Wohlers and Valerija Dobricic and Lefkos Middleton and Lill, \{Christina M.\} and Robert Perneczky and Lars Bertram",

year = "2019",

month = nov,

doi = "10.1016/j.jalz.2019.06.4952",

language = "English",

volume = "15",

pages = "1468--1477",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc",

number = "11",

}

TY - JOUR

T1 - Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid

AU - Takousis, Petros

AU - Sadlon, Angélique

AU - Schulz, Jessica

AU - Wohlers, Inken

AU - Dobricic, Valerija

AU - Middleton, Lefkos

AU - Lill, Christina M.

AU - Perneczky, Robert

AU - Bertram, Lars

PY - 2019/11

Y1 - 2019/11

N2 - Introduction: Several microRNAs (miRNAs) have been implicated in Alzheimer's disease pathogenesis, but the evidence from individual case-control studies remains inconclusive. Methods: A systematic literature review was performed, followed by standardized multistage data extraction, quality control, and meta-analyses on eligible data for brain, blood, and cerebrospinal fluid specimens. Results were compared with miRNAs reported in the abstracts of eligible studies or recent qualitative reviews to assess novelty. Results: Data from 147 independent data sets across 107 publications were quantitatively assessed in 461 meta-analyses. Twenty-five, five, and 32 miRNAs showed studywide significant differential expression (α < 1·08 × 10−4) in brain, cerebrospinal fluid, and blood-derived specimens, respectively, with 5 miRNAs showing differential expression in both brain and blood. Of these 57 miRNAs, 13 had not been reported in the abstracts of previous original or review articles. Discussion: Our systematic assessment of differential miRNA expression is the first of its kind in Alzheimer's disease and highlights several miRNAs of potential relevance.

AB - Introduction: Several microRNAs (miRNAs) have been implicated in Alzheimer's disease pathogenesis, but the evidence from individual case-control studies remains inconclusive. Methods: A systematic literature review was performed, followed by standardized multistage data extraction, quality control, and meta-analyses on eligible data for brain, blood, and cerebrospinal fluid specimens. Results were compared with miRNAs reported in the abstracts of eligible studies or recent qualitative reviews to assess novelty. Results: Data from 147 independent data sets across 107 publications were quantitatively assessed in 461 meta-analyses. Twenty-five, five, and 32 miRNAs showed studywide significant differential expression (α < 1·08 × 10−4) in brain, cerebrospinal fluid, and blood-derived specimens, respectively, with 5 miRNAs showing differential expression in both brain and blood. Of these 57 miRNAs, 13 had not been reported in the abstracts of previous original or review articles. Discussion: Our systematic assessment of differential miRNA expression is the first of its kind in Alzheimer's disease and highlights several miRNAs of potential relevance.

UR - https://www.scopus.com/pages/publications/85071722717

U2 - 10.1016/j.jalz.2019.06.4952

DO - 10.1016/j.jalz.2019.06.4952

M3 - Journal articles

C2 - 31495604

AN - SCOPUS:85071722717

SN - 1552-5260

VL - 15

SP - 1468

EP - 1477

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 11

ER -

Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this